Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma
Journal of the American Animal Hospital Association · 2024
DOI: 10.5326/jaaha-ms-7372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Animal Hospital Association, 2024. Verfasst von Margaret E Duckett und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University (M.D., K.M.C., H.L.); and. Hauptthemen laut MEDLINE: Dog Diseases, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Dogs diagnosed with multicentric lymphoma often relapse following induction therapy within the first year of treatment. The primary aim of this study was to evaluate the tolerability of a novel drug combination using melphalan, vincristine, and cytarabine (MOC) for the treatment of relapsed lymphoma. On day 1, dogs were treated with vincristine (0.5–0.6 mg/m 2 IV) and cytarabine (300 mg/m 2 IV over 4–6 hr or subcutaneously over 2 days). On day 7, dogs were treated with melphalan (20 mg/m 2 per os ). This 2 wk protocol was repeated for at least three cycles or until treatment failure. Twenty-six dogs were treated with MOC and met the inclusion criteria. Twenty-three dogs had toxicity data, and all experienced adverse events with the majority graded as mild. The overall response rate was 38%, which included 19% of dogs who achieved a complete response. The median progression-free survival was 29 days (range 1–280 days). The overall clinical benefit was 65% for a median of 37 days (range 33–280 days). MOC is a safe treatment option for relapsed lymphoma in dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University (M.D., K.M.C., H.L.); and.
- The Ohio State University, Columbus, Ohio (S.B.).
Zitieren
APA
Duckett, M. E., Curran, K. M., Bracha, S., & Leeper, H. J. (2024). Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma. Journal of the American Animal Hospital Association. https://doi.org/10.5326/jaaha-ms-7372
Vancouver
Duckett ME, Curran KM, Bracha S, Leeper HJ. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma. Journal of the American Animal Hospital Association. 2024. doi:10.5326/jaaha-ms-7372
BibTeX
@article{Duckett2024,
author = {Duckett, Margaret E and Curran, Katie M and Bracha, Shay and Leeper, Haley J},
title = {Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma},
journal = {Journal of the American Animal Hospital Association},
year = {2024},
doi = {10.5326/jaaha-ms-7372}
}
EUVIMED